

AMENDMENTS TO THE CLAIMS:

This listing of the claims will replace all prior versions and listing of claims in this application.

1. **(Withdrawn)** A pharmaceutical composition for preventing or treating a Th1-mediated immune disease, which comprises as an active ingredient a substance capable of acting on the natriuretic peptide receptor guanylyl cyclase A to enhance the production of cyclic guanosine monophosphate in an amount effective to prevent or treat a Th1-mediated immune disease.
2. **(Withdrawn)** The pharmaceutical composition according to claim 1, wherein the Th1-mediated immune disease is a disease due to graft rejection following transplantation, graft-versus-host disease caused by bone marrow transplantation, or an autoimmune disease.
3. **(Withdrawn)** The pharmaceutical composition according to claim 2, wherein the autoimmune disease is autoimmune hepatitis, chronic rheumatoid arthritis, insulin-dependent diabetes mellitus, ulcerative colitis, Crohn's disease, multiple sclerosis, autoimmune myocarditis, psoriasis, scleroderma, myasthenia gravis, multiple myositis/dermatomyositis, Hashimoto's disease, autoimmune hypocytosis, pure red cell aplasia, aplastic anemia, Sjogren's syndrome, vasculitis syndrome, or systemic lupus erythematosus.
4. **(Withdrawn)** The pharmaceutical composition according to claim 3, wherein the autoimmune disease is Crohn's disease or multiple sclerosis.
5. **(Withdrawn)** The pharmaceutical composition according to claim 1, wherein the substance capable of acting on the natriuretic peptide receptor guanylyl cyclase A to enhance the production of cyclic guanosine monophosphate is a natriuretic peptide.
6. **(Withdrawn)** The pharmaceutical composition according to claim 5, wherein the natriuretic peptide is atrial natriuretic peptide or brain natriuretic peptide.

7. **(Withdrawn)** The pharmaceutical composition according to claim 6, wherein the atrial natriuretic peptide is of human origin.
8. **(Currently Amended)** A method for treating a Th1-mediated immune disease, ~~which comprises administering a substance capable of acting on the natriuretic peptide receptor guanylyl cyclase A to enhance the production of cyclic guanosine monophosphate~~ comprising administering an atrial natriuretic peptide or brain natriuretic peptide, wherein said Th1-mediated immune disease is a disease due to graft rejection following transplantation or multiple sclerosis.
9. **(Currently Amended)** The method according to claim 8, wherein the Th1-mediated immune disease is ~~selected from a disease due to graft rejection following transplantation; graft versus host disease caused by bone marrow transplantation, or an autoimmune disease.~~
10. **(Currently Amended)** The method according to claim ~~[[9]]~~ 8, wherein the Th1-mediated immune disease is ~~autoimmune disease is autoimmune hepatitis, chronic rheumatoid arthritis, insulin dependent diabetes mellitus, ulcerative colitis, Crohn's disease, multiple sclerosis, autoimmune myocarditis, psoriasis, scleroderma, myasthenia gravis, multiple myositis/dermatomyositis, Hashimoto's disease, autoimmune hypocyctosis, pure red cell aplasia, aplastic anemia, Sjogren's syndrome, vasculitis syndrome, or systemic lupus erythematosus.~~
11. **(Cancelled)**
12. **(Cancelled)**
13. **(Cancelled)**
14. **(Currently Amended)** The method according to claim ~~[[13]]~~ 8, wherein the atrial natriuretic peptide is of human origin.

15. **(Withdrawn)** A method of manufacturing a pharmaceutical composition for preventing or treating a Th1-mediated immune disease comprising admixing a substance capable of acting on the natriuretic peptide receptor guanylyl cyclase A to enhance the production of cyclic guanosine monophosphate with a pharmacologically acceptable carrier, excipient or diluent.
16. **(Withdrawn)** The method according to claim 15, wherein the Th1-mediated immune disease is selected from a disease due to graft rejection following transplantation, graft-versus-host disease caused by bone marrow transplantation, or an autoimmune disease.
17. **(Withdrawn)** The method according to claim 16, wherein the autoimmune disease is autoimmune hepatitis, chronic rheumatoid arthritis, insulin-dependent diabetes mellitus, ulcerative colitis, Crohn's disease, multiple sclerosis, autoimmune myocarditis, psoriasis, scleroderma, myasthenia gravis, multiple myositis/dermatomyositis, Hashimoto's disease, autoimmune hypocytosis, pure red cell aplasia, aplastic anemia, Sjogren's syndrome, vasculitis syndrome, and systemic lupus erythematosus.
18. **(Withdrawn)** The method according to claim 17, wherein the autoimmune disease is Crohn's disease or multiple sclerosis.
19. **(Withdrawn)** The method according to claim 15, wherein the substance capable of acting on the natriuretic peptide receptor guanylyl cyclase A to enhance the production of cyclic guanosine monophosphate is a natriuretic peptide.
20. **(Withdrawn)** The method according to claim 19, wherein the natriuretic peptide is atrial natriuretic peptide or brain natriuretic peptide.
21. **(Withdrawn)** The method according to claim 20, wherein the atrial natriuretic peptide is of human origin.

22. (**Currently Amended**) A method for regulating the Th1/Th2 balance in the immune system, ~~which comprises~~ comprising treating dendritic cells with ~~an substance capable of acting on the natriuretic peptide receptor guanylyl cyclase A to enhance the production of cyclic guanosine monophosphate~~ atrial natriuretic peptide or brain natriuretic peptide, ~~[[and]]~~ thereby polarizing T cells toward Th2-promoting phenotype.
23. (**Cancelled**)
24. (**Cancelled**)
25. (**Currently Amended**) The method according to claim ~~[[24]]~~ 22, wherein the atrial natriuretic peptide or brain natriuretic peptide is of human origin.